A study by researchers from the University of Granada, the University of Wisconsin-Madison and Columbia University has provided new data on the Q10 coenzyme (CoQ10), a molecule which is synthesized within the cells of the organism itself and which has essential functions for cellular metabolism. This study opens the door for the development of tools to modulate the synthesis of CoQ10 in human cells according to their metabolic needs. This will be particularly important for the treatment of diseases caused by primary and secondary deficiencies in CoQ10. The study is published in the journal PNAS.
Its role in the production of energy required by the cell and its antioxidant capacity are among the best known functions of this coenzyme. Human cases have been described in which the deficiency in CoQ10 can be attributed to defects in the biosynthetic pathway, which causes a syndrome with a very heterogeneous clinical picture.
CoQ10 deficiency is a rare mitochondrial disease which affects mostly children. The details of this biosynthetic pathway are not known in their totality, since there are steps whose catalysing enzymes remain unknown, or proteins in the pathway whose specific function is either unknown or has not yet been fully demonstrated.
One of those proteins is Coq9, which the researchers demonstrated in 2013 is an essential protein in the biosynthesis of CoQ, and which specifically regulates the Coq7 protein, an enzyme with a hydroxylase activity that catalyses one of the intermediate steps for the synthesis of CoQ10.
The team state that this research conclusively proves that protein CoQ9 regulates enzyme CoQ7.
The team summise that through the crystallization of the human protein and experiments conducted on mice, the study proves that Coq9 has a lipid-binding structure, which would give it the capacity to provide enzyme Coq7 with the intermediary metabolite that it uses as a substrate in the reaction it catalyses.
The results of the study suggest, besides, that the biosynthetic machinery of CoQ10 is organized as a multiprotein complex in mammals, with the purpose of increasing the efficiency of its synthesis and enable its regulation.
Source: University of Granada
Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.
Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.
Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio, BioPortfolio.com, the life science, pharmaceutical and healthcare portal.
Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.
Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.
An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.